Non–US-born 2019–2020 NHANES study participants >6 years of age and all study participants >60 years of age were eligible to be tested for TB infection using an interferon-gamma release assay (IGRA), QuantiFERON-TB Gold Plus (QIAGEN, https://www.qiagen.com). We selected those specific subpopulations of persons because of their high IGRA test positivity in previous studies (8,11), the potential for complications of TB disease in the >60 age group, and the high risk of LTBI progressing to TB disease among non–US-born persons (11). We excluded persons in those subpopulations who did not undergo phlebotomy as part of the routine NHANES exam. Data for coexisting conditions were not available in the 2019–2020 NHANES dataset (12). All IGRA test results were provided by a single Clinical Laboratory Improvement Act–certified laboratory. Qualitative results were reported for each IGRA test result based on criteria provided by the manufacturer. We used R statistical software (The R Foundation for Statistical Computing, https://www.R-project.org) to obtain frequencies and percentages of eligible NHANES participants with positive TB test results by demographic characteristics. Because of NCHS confidentiality policy, Research Data Center results were suppressed for all categories and subcategories that had <5 responses (13).

In the 2019–2020 NHANES study, 837 non–US-born participants >6 years of age were tested for TB infection, of whom 85 (10%) had positive TB test results (Table). Among non–US-born study participants who tested positive for TB, 51% (43/85) identified as non-Hispanic Asian and 35% (30) as Hispanic; 79% (67) had been in the United States for >5 years. In comparison, among all non–US-born study participants (irrespective of TB test results), 35% (290) identified as non-Hispanic Asian and 43% (356) as Hispanic.

Among the NHANES study participants who were >60 years of age (including both US-born and non–US-born persons), 1,123 were tested for TB, among whom 81 (7%) had positive TB test results (Table). Among those who tested positive for TB, 43% (35) identified as non-Hispanic Black. Among study participants >60 years of age, those with TB-positive test results were less likely than the overall total to identify as non-Hispanic White (21% vs. 44%), more likely to be living in poverty (17.3% vs. 14.4%), less likely to have at least a high school diploma (32.1% vs. 20.5%), and more likely to have been born outside the United States (29.6% vs. 15.9%).

All TB-positive non–US-born NHANES study participants >6 years of age and TB-positive participants >60 years of age were more likely to identify within racial and ethnic minority groups, not have at least a high school diploma, and be living in poverty than overall study participants in each of those subpopulations. In addition, participants >60 years of age who tested positive for TB were more likely to have been born outside the United States than overall study participants >60 years of age. Although not directly comparable across studies, data from our study about demographic differences between TB-positive and overall study participants for both subpopulations were consistent with previous research (8,11).

Comparing data between the 2019–2020 and previous NHANES studies was also limited by a change in the way participants were classified into US-born or non–US-born categories. For the 2019–2020 survey cycle, NHANES study participants were considered US-born if born in a state or the District of Columbia within the United States or in a US-affiliated territory; for the 2011–2012 study, participants born in a US-affiliated territory were considered non–US-born. Because country of birth is one of the most critical stratification factors for examining characteristics of LTBI, defining country of birth consistently will be essential in future NHANES survey cycles that include TB testing.

Although the 2019–2020 NHANES TB test results were not representative of the US population, study data still indicate that TB infection remains a critical health screening consideration among non–US-born persons and persons >60 years of age. Therefore, persons in these subpopulations should be prioritized for TB testing and, if TB infection is diagnosed, treated with an appropriate regimen to prevent progression to active TB disease (14,15). Furthermore, the likely disruption of testing and treatment of TB infection that occurred because of the COVID pandemic suggests we still have much to do if we are to eliminate TB in the United States (1).